Trial · NCT03223714
Conbercept Ophthalmic Injection for Patients of Central Retinal Vein Occlusion
NCT03223714, Phase 3, Completed, Chengdu Kanghong Biotech Co., Ltd.
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Conbercept Ophthalmic Injection for Patients of Central Retinal Vein Occlusion. Trials, record NCT03223714. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03223714
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Conbercept Ophthalmic Injection for Patients of Central Retinal Vein Occlusion
- NCT number
- NCT03223714
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 242 participants, actual
- Lead sponsor
- Chengdu Kanghong Biotech Co., Ltd.
- Conditions
- Macular Edema, Central Retinal Vein Occlusion
- Interventions
- Conbercept Ophthalmic Injection, sham injection
- First posted
- 2017-07-21
- Last updated
- 2022-07-13
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Best Corrected Visual Acuity | month 6 | To compare mean changes in Best Corrected Visual Acuity (BCVA) from baseline between the Conbercept ophthalmic injection treatment group (treatment group) and the control group at month 6. |
| Secondary | Best Corrected Visual Acuity | month 3 and month 12 | To evaluate mean changes in BCVA from baseline of the treatment group and the control group at month 3 and 12. |
| Secondary | Central Retinal Thickness | month 3, month6 and month 12 | To evaluate mean changes in Central Retinal Thickness (CRT) from baseline of the treatment group and the control group at month 3, 6 and 12. |
| Secondary | Number of subject who received laser rescue treatment | month 6 and month 12 | To evaluate the number of subjects who received laser rescue treatment of the treatment group and the control group at month 6 and 12. |
| Secondary | Number of participants with treatment-related the systemic and ocular safely as assessed | month 6 and month 12 or trail period | To evaluate the systemic and ocular safety of the treatment group and the control group. |
| Other | distribution of BCVA changes | month 3, month 6 and month 12 | To evaluate the distribution of BCVA changes from baseline of the treatment group and the control group at month 3, 6 and 12. |
| Other | Mean change in Best Corrected Visual Acuity | month 0,month 1,month 2,month 3,month 4,month 5,month 6,month 7,month 8,month 9,month 10,month 11 and month 12 | To evaluate mean changes in BCVA from baseline of the treatment group and the control group at every visit for 1 year. |
| Other | Mean changes in CRT, Macular Volume | month 0,month 1,month 2,month 3,month 4,month 5,month 6,month 7,month 8,month 9,month 10,month 11 and month 12 | To evaluate the average changes in imaging findings (e.g., CRT and total macular volume) relative to the baseline for treatment group and control group at each follow-up visit for 1 year |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03223714
GET https://conductscience.org/api/trials/v1/NCT03223714/registered